Zacks Investment Research Lowers Natus Medical (NASDAQ:NTUS) to Hold

Natus Medical (NASDAQ:NTUSGet Rating) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research report issued on Tuesday, Zacks.com reports.

According to Zacks, “Natus Medical Incorporated is a leading provider of healthcare products used for the screening, detection, treatment, monitoring and tracking of common medical ailments such as hearing impairment, neurological dysfunction, epilepsy, sleep disorders, and newborn care. Product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, and software systems for managing and tracking disorders and diseases for public health laboratories. “

Separately, StockNews.com started coverage on Natus Medical in a research note on Thursday, March 31st. They set a “strong-buy” rating on the stock.

Shares of Natus Medical stock opened at $33.13 on Tuesday. Natus Medical has a 52 week low of $20.90 and a 52 week high of $33.93. The company has a fifty day simple moving average of $27.48. The firm has a market cap of $1.14 billion, a price-to-earnings ratio of 87.19 and a beta of 0.47.

Natus Medical (NASDAQ:NTUSGet Rating) last posted its earnings results on Thursday, February 24th. The company reported $0.47 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.03. Natus Medical had a return on equity of 9.75% and a net margin of 2.78%. The firm had revenue of $128.66 million for the quarter, compared to analyst estimates of $128.00 million. During the same quarter in the prior year, the company earned $0.39 EPS. On average, research analysts forecast that Natus Medical will post 1.44 earnings per share for the current year.

Hedge funds have recently bought and sold shares of the business. UMB Bank N A MO acquired a new stake in Natus Medical in the 4th quarter valued at about $29,000. First Horizon Advisors Inc. raised its position in Natus Medical by 1,529.9% in the 4th quarter. First Horizon Advisors Inc. now owns 1,581 shares of the company’s stock valued at $37,000 after purchasing an additional 1,484 shares in the last quarter. Pinebridge Investments L.P. acquired a new stake in Natus Medical in the 4th quarter valued at about $50,000. Royal Bank of Canada raised its position in Natus Medical by 612.8% in the 2nd quarter. Royal Bank of Canada now owns 2,851 shares of the company’s stock valued at $74,000 after purchasing an additional 2,451 shares in the last quarter. Finally, Heritage Wealth Management LLC increased its holdings in shares of Natus Medical by 43.5% in the 3rd quarter. Heritage Wealth Management LLC now owns 3,114 shares of the company’s stock valued at $78,000 after acquiring an additional 944 shares during the last quarter. 92.35% of the stock is currently owned by institutional investors.

Natus Medical Company Profile (Get Rating)

Natus Medical Incorporated provides medical device solutions focuses on the diagnosis and treatment of patients with central nervous and sensory system disorders worldwide. It offers products and technologies used for the screening, detection, treatment, monitoring, and tracking of common medical ailments in newborn care, hearing impairment, neurological and neurosurgical treatments, epilepsy, sleep disorders, and neuromuscular diseases.

Further Reading

Get a free copy of the Zacks research report on Natus Medical (NTUS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Natus Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical and related companies with MarketBeat.com's FREE daily email newsletter.